Presentation on Japan First Strategy at Ord Minnett
Sydney, Nov 1, 2017 AEST (ABN Newswire) - Regeneus Ltd (
ASX:RGS) provides the Company's Presentation on Japan First Strategy at Ord Minnett.
Company Snapshot
3 world class-technology platforms
- Allogeneic adult stem cells (MSCs) from adipose tissue for osteoarthritis and other inflammatory conditions (Progenza, CryoShot)
- Immuno-therapy for oncology (RGSH4K, Kvax)
- Cell-free secretions from MSCs focused on dermatology and inflammatory skin conditions (Sygenus)
Diversified portfolio of clinical stage products
- Human and animal health markets
- Multiple product opportunities addressing multiple significant unmet medical needs - many shots on goal
- Technology supported by emerging positive clinical data
- Scalable manufacturing for allogeneic stem cells
- IP portfolio underpins technology and product pipeline for wide range of inflammatory indications
- Licence driven business model
Driven by innovation and collaboration
- Track record of technology innovation and rapid translation to the clinic
- Successful technology and clinical collaborations (AGC, Kolling Institute, Macquarie and Adelaide Unis)
- Experienced and commercially focused management team and Board
- Well positioned to unlock significant value over next 12 months
Japan First Strategy
- Most Australian biotechs seek to license for US and EU markets first
- Japan first strategy takes advantage of globally attractive market conditions
o fast-track regulatory environment for RM products
-- shorter phase 2 trial - "probable efficacy"
-- Conditional Approval 5-7 years means no requirement for phase 3
-- can commercialise product during CA phase
-- 70% government reimbursement includes CA phase
o supportive regulator - PMDA and government departments
o high level of industry engagement for market sector - FIRM >250 members
- Focus on product manufacturing and standardization allows for separating manufacturing and clinical licensing transactions
- Licensees willing to do Japan only transactions - benchmarks marks value and leaves other territories available
- Japan can validate opportunity for other markets
- Other jurisdictions influenced by new regulatory framework - eg South Korea and USA
To view the presentation, please visit:
http://abnnewswire.net/lnk/RQX8AES4
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
